Navigation Links
SkinMedica Launches Redness Relief CalmPlex™
Date:2/3/2011

CARLSBAD, Calif., Feb. 3, 2011 /PRNewswire/ -- SkinMedica, Inc., the fastest-growing professional skin care company in the United States, today announced that it is introducing a new, fast-acting anti-redness product, Redness Relief CalmPlex™—the biggest innovation in redness in over two decades.  It is the first and only non-prescription product clinically proven to reduce visible redness.    

(Photo: http://photos.prnewswire.com/prnh/20110203/NY41924 )

(Logo: http://photos.prnewswire.com/prnh/20100810/NY48207LOGO)

This revolutionary formula contains, CalmPlex™, a patented, nature-inspired ingredient that treats the underlying causes of redness by inhibiting the release of a key natural vasodilator as well as niacinamide which helps to strengthen the skin by supporting the barrier function.  

"Visible redness is a real and emotional burden for millions of people," commented SkinMedica Founder, Richard Fitzpatrick, MD.  "As dermatologists, we have been frustrated by the lack of effective approaches to reducing the appearance of redness.  Backed by solid science and clinical results, Redness Relief CalmPlex™ represents a truly novel advance in the skin aesthetics area."

Ideal for sensitive skin types, this non-comedogenic formula contains no added fragrance and offers relief and results to improve overall skin appearance by neutralizing unwanted redness.

CLINICAL STUDIES:

In multiple clinical studies, Redness Relief CalmPlex™ demonstrated efficacy in relieving visible redness and improving overall skin tone. SkinMedica Redness Relief CalmPlex™ demonstrated a 40% reduction in UV-induced redness in as early as 3 days. Redness Relief CalmPlex™ also provided significant reductions in chronic redness after 1 week with continued improvement through week twelve.

Physicians assessing the clinical study reported the following results after only four weeks:

  • 43% reduction in appearance of visible redness
  • 51% improvement in evenness of skin tone
  • 49% improvement in overall severity

Participants in the study reported the following results at Week 4:

  • 78% of subjects reported an improvement in overall condition
  • 72% of subjects reported a reduction in visible redness
  • High patient satisfaction; 100% of subjects liked the product

SkinMedica Redness Relief CalmPlex™ launched the second week of January and is available through licensed physicians and medically supervised spas. Visit SkinMedica.com for locations.

About SkinMedica

SkinMedica, Inc. is focused on developing, acquiring and commercializing products that treat dermatologic conditions and improve the appearance of skin. The Company markets and sells to physicians, with a focus on aesthetics, both prescription and non-prescription skin care products. The Company's full line of aesthetic skin care products includes the revolutionary TNS Essential Serum™ and hallmark TNS Recovery Complex®. The formulations in the Company's clinical skin care collection enhance skin appearance, reduce signs of aging and provide other skin care benefits.

SkinMedica's prescription products include VANIQA® (eflornithine hydrochloride) Cream, 13.9%, the only FDA-approved prescription product for the reduction of unwanted facial hair in women and EpiQuin® Micro Cream (4% hydroquinone) for hyperpigmentation, or "brown spots" that commonly result from aging, inflammation or sun exposure.

SkinMedica is based in Carlsbad, California. For more information, visit: www.skinmedica.com.

TNS Recovery Complex®, VANIQA®, EpiQuin® Micro, and SkinMedica®, are registered trademarks of SkinMedica, Inc and affiliates.


'/>"/>
SOURCE SkinMedica, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Launches Senior Notes Offering
2. Merz Launches New Online Resource for Patients with Focal Dystonias
3. Thats Nice LLC Launches Nice Insight Marketing Intelligence for CRAMs With Its Pharma & Biotech Outsourcing Survey
4. REMCON Plastics Launches Aggressive 5 year Plan by Hiring New National Sales and Marketing Professional
5. Avantra Biosciences Launches Multiplex System for Faster, Easier Quantification of Cancer Protein Biomarkers
6. Global Coalition on Aging Launches as 450 Million People Turn 65 Over Next Two Decades
7. eCareSoft Launches Comprehensive EHR for Small & Medium Hospitals
8. TheCarrot.com Launches Quit Smoking Program
9. Nonin Medical, Inc. Launches New WristOx2™, Model 3150 in U.S. and Canada
10. MMIS, Inc. Launches the MediSpend™ Aggregate Spend Solution
11. Digital Display System Specialist Jayex Launches Med-Extranet Online Media Library
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Leading ... that address medical conditions resulting from a breakdown ... has appointed Greg Doyle as chief ... Leading BioSciences, executive management team and board of ... chief financial officer. He will provide continued leadership ...
(Date:6/23/2016)... June 23, 2016 Research and ... in Europe 2016 Edition: The New Global Agenda " ... OTC Distribution in Europe - ... explores and tracks change. It identifies the driving factors coming ... the consumer healthcare industry now and in the future. It ...
(Date:6/23/2016)... June 23, 2016 The ... the development of combination therapies trend is expected ... treatment of CLL were available only in the ... are chlorambucil in combination with prednisone, and a ... a growing trend of developing combination therapies to ...
Breaking Medicine Technology:
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
(Date:6/24/2016)... Norcross, Georgia (PRWEB) , ... June 24, 2016 ... ... Year” awards today at the Clinical Decision Making in Emergency Medicine conference in ... who have authored journal articles published in Emergency Medicine Practice and ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, ... stem (iPS) cells and other difficult to transfect cells, announces its launch of ... PluriQ™ G9™ Gene Editing System is a complete system for culturing and ...
(Date:6/24/2016)... ... June 24, 2016 , ... To succeed under value-based payments, ... are unsure how to move forward, given the need to sustain current operations. ... tailored to an organization’s specific needs. , PYA Principal Martie Ross states, “Healthcare ...
Breaking Medicine News(10 mins):